Tier 4 — mechanistic

Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia

Veenhuis SJG, van Os NJH, Janssen AJWM, van Gerven MHJC, Coene KLM, Engelke UFH, Wevers RA, Tinnevelt GH, Ter Heine R, van de Warrenburg BPC, Weemaes CMR, Roeleveld N, Willemsen MAAP
Movement disorders : official journal of the Movement Disorder Society 2021 36; 12; 2951-2957

Bibliography

PubMed
PMID 34515380
PubMed Central
PMC9291897
DOI
10.1002/mds.28788
Funding
Ataxia Telangiectasia Children’s Project, Twan Foundation and research infrastructure support.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignOpen-label human intervention study
ModelHuman participants
Sample24 people with ataxia telangiectasia
InterventionOral NR in an open-label proof-of-concept study
Duration4 months, with assessment after withdrawal
EndpointsAtaxia scores; immunoglobulins; tolerability

What the study showed, in plain terms

Ataxia scores and selected immunoglobulin measures improved during NR use, with worsening of ataxia measures after withdrawal.

Key findings

Ataxia scores and selected immunoglobulin measures improved during NR use, with worsening of ataxia measures after withdrawal.

What this study can and cannot tell us

No placebo control; a rare-disease proof-of-concept study cannot establish general anti-aging or pediatric use.

Related papers in the corpus

Tier 4
Long-Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia
Presterud R et al. · Movement disorders : official journal of the Movement Disorder Society · 2024
Tier 4
Nicotinamide Riboside for Ataxia Telangiectasia: A Report of an Early Treated Individual
Steinbrücker K et al. · Neuropediatrics · 2023
Tier 2
Safety and efficacy of individualised exercise and NAD+ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial
Lin KY et al. · The Lancet. Neurology · 2026
Tier 4
Effects of nicotinamide riboside in mitochondrial DNA disease
Katherine R. Schon et al. · Genome Medicine · 2026
Tier 2
Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial
Shoji M et al. · Aging cell · 2025
Tier 4
ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis
Van Hove JLK et al. · Mitochondrion · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology